Delivering clinical research to make patients, and the NHS, better Breast SSG Sept 2015 Research Duncan Wheatley Clinical and Sub Specialty Research Lead Wendy Cook, Research Delivery Manager dd/mm/yyyy

Breast Tumour Group National Perspective Data from Portfolio ODP – Cut off 21/08/15

Breast Tumour Group National Perspective LCRN 2014/ /2016 CommercialNon-CommercialTotalRankCommercialNon-CommercialTotalRank East Midlands Eastern Greater Manchester Kent, Surrey and Sussex North East and North Cumbria North Thames North West Coast North West London South London South West Peninsula Thames Valley and South Midlands Wessex West Midlands West of England Yorkshire and Humber Data from Portfolio ODP – Cut off 21/08/15

Breast Tumour Group Open Studies East Midlands Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes12 An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo7 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo226 CANC OLYMPIA17117CommercialInterventionalNo1 CANC MBC - disease registry study18055CommercialObservationalNo7 EPHOS-B5501Non-CommercialInterventionalNo1 FAST-Forward10896Non-CommercialInterventionalNo83 FOAM Trial18588Non-CommercialInterventionalNo1 IMPORT HIGH2254Non-CommercialInterventionalNo111 LATTE6509Non-CommercialObservationalNo23 MAMMO Non-CommercialBothYes123 MANTA15689Non-CommercialInterventionalNo6 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo292 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6 NCRN / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo1 NCRN Enzalutamide with Trastuzumab in HER2+ AR+ MBCa16492CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC 13595CommercialInterventionalNo1 NCRN559 HERBIO: ABP 980 vs trastuzumab in HER2+ early BC14623CommercialInterventionalNo5 PAKT16095Non-CommercialInterventionalNo4 POSNOC16069Non-CommercialInterventionalYes13 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)28 RAPPER1471Non-CommercialObservationalYes (LC)276 SEARCH1390Non-CommercialObservationalYes (LC)236 Data from Portfolio ODP – Cut off 21/08/15

Breast Tumour Group Open Studies Eastern Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo31 CANC MBC - disease registry study18055CommercialObservationalNo2 Chemo-NEAR10052Non-CommercialObservationalYes (LC)11 FAST-Forward10896Non-CommercialInterventionalNo447 IMPORT HIGH2254Non-CommercialInterventionalNo683 LATTE6509Non-CommercialObservationalNo28 LORIS16736Non-CommercialInterventionalNo1 MAMMO Non-CommercialBothYes37 MANTA15689Non-CommercialInterventionalNo7 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6 NCRN OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo1 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo5 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo1 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo2 PAKT16095Non-CommercialInterventionalNo3 POSEIDON18165Non-CommercialInterventionalNo5 POSNOC16069Non-CommercialInterventionalYes4 Prevention of Lymphoedema after Clearance by External Compression (PLACE) 9074Non-CommercialBothYes (LC)1 Proteins CTCF and BORIS as biomarkers in breast and prostate cancers5712Non-CommercialObservationalNo1,017 RADICAL11456Non-CommercialInterventionalNo13 RAPPER1471Non-CommercialObservationalYes (LC)662 SEARCH1390Non-CommercialObservationalYes (LC)12,153

Breast Tumour Group Open Studies Greater Manchester 1 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN ID Study TypeStudy Design Open to New Sites? Total Recruitment An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo23 B-AHEAD3: Breast Activity and Healthy Eating After Diagnosis Non-CommercialInterventionalNo2 Breast Cancer Risk Communication17977Non-CommercialObservationalNo38 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo43 BRRIDE 2 Breast Risk Reduction Intermittent Diet Evaluation18052Non-CommercialInterventionalNo27 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 CANC MBC - disease registry study18055CommercialObservationalNo3 CHAMPion8685Non-CommercialObservationalNo492 Digital breast tomosynthesis in screening younger higher risk women16312Non-CommercialInterventionalNo859 EPHOS-B5501Non-CommercialInterventionalNo60 FAKTION16319Non-CommercialInterventionalYes6 IMPORT HIGH2254Non-CommercialInterventionalNo69 LATTE6509Non-CommercialObservationalNo137 LORIS16736Non-CommercialInterventionalNo1 MAMMO Non-CommercialBothYes205

Breast Tumour Group Open Studies Greater Manchester 2 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo443 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo5 NCRN OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo4 NCRN BMN 673 in patients with metastatic breast cancer and a BRCA mutation 16486CommercialInterventionalNo2 NCRN Enzalutamide with Trastuzumab in HER2+ AR+ MBCa16492CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC13595CommercialInterventionalNo1 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo1 OPPORTUNE11583Non-CommercialInterventionalNo43 POSNOC16069Non-CommercialInterventionalYes27 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)45 PROCAS – Lifestyle Breast Cancer Prevention Feasibility Study17480Non-CommercialInterventionalNo71 RADICAL11456Non-CommercialInterventionalNo2 RAPPER1471Non-CommercialObservationalYes (LC)715 SEARCH1390Non-CommercialObservationalYes (LC)234

Breast Tumour Group Open Studies Kent, Surrey and Sussex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo10 CANC MBC - disease registry study18055CommercialObservationalNo5 EORTC Non-CommercialObservationalNo4 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo3 FAST-Forward10896Non-CommercialInterventionalNo250 IMPORT HIGH2254Non-CommercialInterventionalNo67 LATTE6509Non-CommercialObservationalNo37 MAMMO Non-CommercialBothYes76 MANTA15689Non-CommercialInterventionalNo17 NCRN Neoadjuvant Letrozole and GDC-0032 in ER+/HER2- Breast Cancer 16325CommercialInterventionalNo1 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo8 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo2 OPPORTUNE11583Non-CommercialInterventionalNo15 PAKT16095Non-CommercialInterventionalNo3 POSNOC16069Non-CommercialInterventionalYes9 RAPPER1471Non-CommercialObservationalYes (LC)337 SEARCH1390Non-CommercialObservationalYes (LC)15

Breast Tumour Group Open Studies North East and North Cumbria Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo21 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYes89 EPHOS-B5501Non-CommercialInterventionalNo7 FAST-Forward10896Non-CommercialInterventionalNo30 IMPORT HIGH2254Non-CommercialInterventionalNo32 LATTE6509Non-CommercialObservationalNo38 MAMMO Non-CommercialBothYes41 MANTA15689Non-CommercialInterventionalNo4 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo5 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes2 RADICAL11456Non-CommercialInterventionalNo5 RAPPER1471Non-CommercialObservationalYes (LC)50 SEARCH1390Non-CommercialObservationalYes (LC)108

Breast Tumour Group Open Studies North Thames Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo41 CANC OLYMPIA17117CommercialInterventionalNo1 EPHOS-B5501Non-CommercialInterventionalNo6 FAST-Forward10896Non-CommercialInterventionalNo207 IMPORT HIGH2254Non-CommercialInterventionalNo194 LATTE6509Non-CommercialObservationalNo19 MAMMO Non-CommercialBothYes60 MANTA15689Non-CommercialInterventionalNo8 OPPORTUNE11583Non-CommercialInterventionalNo14 PAKT16095Non-CommercialInterventionalNo3 PICTURE BREAST Longitudinal17421Non-CommercialObservationalNo22 PICTURE BREAST XS (cross-sectional)16682Non-CommercialObservationalNo72 RAPPER1471Non-CommercialObservationalYes (LC)84 SEARCH1390Non-CommercialObservationalYes (LC)5,692 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes66

Breast Tumour Group Open Studies North West Coast Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo226 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 CANC MBC - disease registry study18055CommercialObservationalNo4 CiPHER16444Non-CommercialInterventionalYes1 EPHOS-B5501Non-CommercialInterventionalNo9 FAST-Forward10896Non-CommercialInterventionalNo204 IMPORT HIGH2254Non-CommercialInterventionalNo229 LATTE6509Non-CommercialObservationalNo36 MAMMO Non-CommercialBothYes77 NCRN / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo2 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC13595CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes8 RAPPER1471Non-CommercialObservationalYes (LC)623 SEARCH1390Non-CommercialObservationalYes (LC)159

Breast Tumour Group Open Studies North West London Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment An exploratory breast lead interval study (EBLIS)15783Non-CommercialObservationalNo86 Breast Screening and Monitoring Study13803Non-CommercialObservationalNo1,238 Chemotherapy induced changes in [18F]ICMT Non-CommercialObservationalNo17 FAST-Forward10896Non-CommercialInterventionalNo86 IMPORT HIGH2254Non-CommercialInterventionalNo27 MAMMO Non-CommercialBothYes52 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo3 NCRN OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo1 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo9 PAKT16095Non-CommercialInterventionalNo1 POPPET16020Non-CommercialObservationalNo3 RADICAL11456Non-CommercialInterventionalNo10 RAPPER1471Non-CommercialObservationalYes (LC)56 SEARCH1390Non-CommercialObservationalYes (LC)17 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes5 VERB Study13222Non-CommercialInterventionalNo5

Breast Tumour Group Open Studies South London 1 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo146 CANC OLYMPIA17117CommercialInterventionalNo10 CANC MBC - disease registry study18055CommercialObservationalNo5 CANC A Study of Ruxolitinib in advanced HER219078CommercialInterventionalNo1 Chemo-NEAR10052Non-CommercialObservationalYes (LC)122 Digital breast tomosynthesis in screening younger higher risk women16312Non-CommercialInterventionalNo266 EPHOS-B5501Non-CommercialInterventionalNo27 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo104 FAST-Forward10896Non-CommercialInterventionalNo210 Functional Assessment of Breast Cancer in Bone (FABB study)13473Non-CommercialObservationalNo18 Immunopathogenesis and Molecular Biology in Breast Cancer Subtypes15152Non-CommercialObservationalYes (LC)378 IMPORT HIGH2254Non-CommercialInterventionalNo233 LATTE6509Non-CommercialObservationalNo9 LORIS16736Non-CommercialInterventionalNo1 Magnetic Sentinel Node and Occult Lesion Localisation (MagSNOLL)14979Non-CommercialInterventionalYes57 MAMMO Non-CommercialBothYes17 MANTA15689Non-CommercialInterventionalNo7 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo153 NCRN Cerenkov Luminescence Imaging in breast cancer16259CommercialInterventionalNo20 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo6

Breast Tumour Group Open Studies South London 2 Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment NCRN / FINESSE - lucitanib in ER+ metastatic BrCa15473CommercialInterventionalNo6 NCRN / BravO niraparib vs physician's choice in HER2- BRCA BrCa15877CommercialInterventionalNo8 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo19 NCRN non-steroidal aromatase inhibitors + LY in breast cancer 17753CommercialInterventionalNo2 NCRN186 ALTERNATIVE - Lapatinib + Traztuzumab + AI in 1st line ER+/HER2+ MBC 11343CommercialInterventionalNo1 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo6 NCRN454 BELLE 3: BKM120 + Fulvestrant in ER+, HER2-, AI, MTOR resistant MBC 13595CommercialInterventionalNo5 OPPORTUNE11583Non-CommercialInterventionalNo39 PAKT16095Non-CommercialInterventionalNo10 PALLET17716Non-CommercialInterventionalYes5 Phase I study of AT13148, a novel AGC kinase inhibitor11846Non-CommercialInterventionalNo40 POSNOC16069Non-CommercialInterventionalYes1 PREHEAT Trial - local heat preconditioning and wound healing18442Non-CommercialInterventionalNo29 Prevention of Lymphoedema after Clearance by External Compression (PLACE) 9074Non-CommercialBothYes (LC)9 RAPPER1471Non-CommercialObservationalYes (LC)1,109 SEARCH1390Non-CommercialObservationalYes (LC)71

Breast Tumour Group Open Studies South West Peninsula Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo14 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo7 CANC MBC - disease registry study18055CommercialObservationalNo10 CANC A Study of Ruxolitinib in advanced HER219078CommercialInterventionalNo2 Chemo-NEAR10052Non-CommercialObservationalYes (LC)34 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYes60 EPHOS-B5501Non-CommercialInterventionalNo19 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo10 FAST-Forward10896Non-CommercialInterventionalNo617 FURVA, Version Non-CommercialInterventionalNo1 IMPORT HIGH2254Non-CommercialInterventionalYes77 LATTE6509Non-CommercialObservationalNo54 LORIS16736Non-CommercialInterventionalNo1 MAMMO Non-CommercialBothYes26 MANTA15689Non-CommercialInterventionalNo9 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo20 NCRN OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer16109CommercialInterventionalNo1 NCRN MONALEESA-2 LEE011 + letrozole in ER+ HER2- advanced BC16241CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo12 OPPORTUNE11583Non-CommercialInterventionalNo23 PAKT16095Non-CommercialInterventionalNo6 PALLET17716Non-CommercialInterventionalYes5 POSNOC16069Non-CommercialInterventionalYes2 RAPPER1471Non-CommercialObservationalYes (LC)232 SEARCH1390Non-CommercialObservationalYes (LC)272

Breast Tumour Group Open Studies Thames Valley and South Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847 Non- Commercial ObservationalNo36 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo2 FAST-Forward10896 Non- Commercial InterventionalNo104 IMPORT HIGH2254 Non- Commercial InterventionalNo42 MAMMO Non- Commercial BothYes2 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo4 POSNOC16069 Non- Commercial InterventionalYes,4 RAPPER1471 Non- Commercial ObservationalYes (LC)26 SEARCH1390 Non- Commercial ObservationalYes (LC)119

Breast Tumour Group Open Studies Wessex Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes4 Body composition & chemo response & toxicity in early breast cancer16944Non-CommercialObservationalNo32 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo43 CANC OLYMPIA17117CommercialInterventionalNo1 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo1 Chemo-NEAR10052Non-CommercialObservationalYes (LC)33 Digital breast tomosynthesis in younger symptomatic women.9918Non-CommercialInterventionalYescountry16 EPHOS-B5501Non-CommercialInterventionalNo150 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo4 FAST-Forward10896Non-CommercialInterventionalNo181 IMPORT HIGH2254Non-CommercialInterventionalNo94 KYN: Alcohol and breast cancer prevention18494Non-CommercialObservationalNo208 LATTE6509Non-CommercialObservationalNo31 MAMMO Non-CommercialBothYes37 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo203 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo2 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 PAKT16095Non-CommercialInterventionalNo1 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)25 RAPPER1471Non-CommercialObservationalYes (LC)27 SEARCH1390Non-CommercialObservationalYes (LC)234 The BeGIN study: Investigating Outcomes from Breast Cancer18500Non-CommercialObservationalNo2 Understanding immunity in lymph nodes. V Non-CommercialObservationalNo42

Breast Tumour Group Open Studies West Midlands Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo22 CANC OLYMPIA17117CommercialInterventionalNo1 CANC MBC - disease registry study18055CommercialObservationalNo4 EPHOS-B5501Non-CommercialInterventionalNo37 FAST-Forward10896Non-CommercialInterventionalNo933 IMPORT HIGH2254Non-CommercialInterventionalNo221 LATTE6509Non-CommercialObservationalNo58 LORIS16736Non-CommercialInterventionalNo3 MAMMO Non-CommercialBothYes212 MANTA15689Non-CommercialInterventionalNo5 Multifrequency Bioimpedance in the Early Detection of Lymphoedema8881Non-CommercialObservationalNo50 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo26 NCRN OlympiAD Olaparib vs Physician's Chioce in BRCA mutated metastatic breast cancer 16109CommercialInterventionalNo4 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo3 PAKT16095Non-CommercialInterventionalNo1 POSNOC16069Non-CommercialInterventionalYes8 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)5 RADICAL11456Non-CommercialInterventionalNo1 RAPPER1471Non-CommercialObservationalYes (LC)725 SEARCH1390Non-CommercialObservationalYes (LC)518

Breast Tumour Group Open Studies West of England Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy Design Open to New Sites? Total Recruitment Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo99 CANC MBC - disease registry study18055CommercialObservationalNo3 CONCEPT (Breast Cancer)17993Non-CommercialInterventionalNo4 EORTC Non-CommercialObservationalNo1 FAST-Forward10896Non-CommercialInterventionalNo162 FURVA, Version Non-CommercialInterventionalYes,3 IMPORT HIGH2254Non-CommercialInterventionalNo269 LATTE6509Non-CommercialObservationalNo35 MAMMO Non-CommercialBothYes,96 MANTA15689Non-CommercialInterventionalNo3 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo1 NCRN BERENICE PERTUZUMAB + TRASTUZUMAB + STANDARD ANTHRACYCLINE CHEMO IN HER2+ BC 16379CommercialInterventionalNo2 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo4 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo2 POSNOC16069Non-CommercialInterventionalYes,6 RAPPER1471Non-CommercialObservationalYes (LC)121 SEARCH1390Non-CommercialObservationalYes (LC)188 TARGIT-B Trial of radiotherapy in higher risk breast cancer patients14208Non-CommercialInterventionalYes1

Breast Tumour Group Open Studies Yorkshire and Humber Data from Portfolio ODP – Cut off 21/08/15 Study Name UKCRN IDStudy TypeStudy DesignOpen to New Sites?Total Recruitment AKT inhibitor in breast cancer (STAKT study)14498Non-CommercialInterventionalYes2 Bridging the Age Gap in Breast Cancer13847Non-CommercialObservationalNo633 CANC OLYMPIA17117CommercialInterventionalNo1 CANC BOUDICA - Everolimus [RAD001] + exemestane in breast cancer17941CommercialObservationalNo2 CANC MBC - disease registry study18055CommercialObservationalNo5 DETECT7266Non-CommercialObservationalNo398 EPHOS-B5501Non-CommercialInterventionalNo45 Evaluating outcomes of immediate breast reconstruction (POBRAD-M)16816Non-CommercialInterventionalNo12 FAST-Forward10896Non-CommercialInterventionalNo110 IMPORT HIGH2254Non-CommercialInterventionalNo219 LATTE6509Non-CommercialObservationalNo265 Lymphocyte phenotype and cytokine production in patients with fatigue.15893Non-CommercialObservationalNo65 MAMMO Non-CommercialBothYes101 MANTA15689Non-CommercialInterventionalNo4 NCRN / KAITLIN TRASTUZUMAB + PERTUZUMAB + TAXANE vs TRASTUZUMAB EMTANSINE + PERTUZUMAB IN BC 15506CommercialInterventionalNo17 NCRN384 KATHERINE: Adjuvant TDM1 in HER 2+ patients with residual disease post neoadjuvant therapy 13395CommercialInterventionalNo13 NCRN628 - TNACITY: 1st LINE nab®- PACLITAXEL + GEMCITABINE/CARBOPLATIN IN TRIPLE NEGATIVE MBC 14714CommercialInterventionalNo7 OPPORTUNE11583Non-CommercialInterventionalNo5 PAKT16095Non-CommercialInterventionalNo1 POSNOC16069Non-CommercialInterventionalYes23 Prevention of Lymphoedema after Clearance by External Compression (PLACE)9074Non-CommercialBothYes (LC)3 RAPPER1471Non-CommercialObservationalYes (LC)222 SEARCH1390Non-CommercialObservationalYes (LC)131

Breast Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15

Breast Tumour Group South West Peninsula Sites Data from Portfolio ODP – Cut off 21/08/15 Trust 2014/ /2016 Commercial Non- Commercial Commercial Non- Commercial Northern Devon Healthcare NHS Trust01203 Plymouth Hospitals NHS Trust43322 Royal Cornwall Hospitals NHS Trust Royal Devon and Exeter NHS Foundation Trust53806 South Devon Healthcare NHS Foundation Trust Taunton and Somerset NHS Foundation Trust Yeovil District Hospital NHS Foundation Trust14106

Breast Tumour Group South West Peninsula Open Studies 1 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrust Investigator Name End DateTargetRecruitment 2015/2016 Recruitment RTT AFFECT6140Non-CommercialPlymouth Hospitals NHS Trust Brewer, Dr Carole 30-Sep AFFECT6140Non-Commercial South Devon Healthcare NHS Foundation Trust Brewer, Dr Carole 30-Sep AKT inhibitor in breast cancer (STAKT study) 14498Non-CommercialPlymouth Hospitals NHS TrustKelly, Dr Steve 14-Jul BOUDICA17941CommercialPlymouth Hospitals NHS TrustKelly, Dr Steve 01-Dec BOUDICA17941Commercial Royal Cornwall Hospitals NHS Trust Thomson, Dr Alastair 31-Dec BOUDICA17941Commercial Royal Devon and Exeter NHS Foundation Trust Scatchard, Dr Kate 31-Dec BOUDICA17941Commercial Taunton and Somerset NHS Foundation Trust Barthakur, Urmila 00 CANC MBC - disease registry study Esther 18055CommercialPlymouth Hospitals NHS TrustDubey, Dr Sid 31-Mar CANC MBC - disease registry study Esther 18055Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 27-Feb Chemo-NEAR10052Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar Chemo-NEAR10052Non-Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini 01-Dec CO-OPS13796Non-CommercialPlymouth Hospitals NHS TrustSteel, Mr Jim 31-Dec Digital breast tomosynthesis in younger symptomatic women. 9918Non-CommercialPlymouth Hospitals NHS TrustSteel, Mr Jim 30-Nov EPHOS-B5501Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hong, Dr Anne 31-Jul EPHOS-B5501Non-Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 30-Sep

Breast Tumour Group South West Peninsula Open Studies 2 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrustInvestigator NameEnd DateTargetRecruitment 2015/2016 Recruitment RTT Evaluating outcomes of immediate breast reconstruction (POBRAD-M) 16816Non-Commercial Royal Cornwall Hospitals NHS Trust Brown, Mr Iain 11-Feb FURVA18232Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Dec FURVA18232Non-Commercial Royal Devon and Exeter NHS Foundation Trust Hong, Dr Anne 01-May IMPORT HIGH2254Non-Commercial Plymouth Hospitals NHS Trust Kelly, Dr Steve 01-Jun IMPORT HIGH2254Non-Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 24-Mar IMPORT HIGH2254Non-Commercial South Devon Healthcare NHS Foundation Trust Bliss, Dr Peter 30-Apr LORIS16736Non-Commercial Royal Cornwall Hospitals NHS Trust Barta, Dr Miklos 31-Aug LORIS16736Non-Commercial Royal Devon and Exeter NHS Foundation Trust Ferguson, Mr Douglas 01-Aug MAMMO Non-Commercial Royal Cornwall Hospitals NHS Trust Barta, Dr Miklos 22-Apr MAMMO Non-Commercial Royal Devon and Exeter NHS Foundation Trust Ferguson, Mr Douglas 30-Jun MAMMO Non-Commercial South Devon Healthcare NHS Foundation Trust Donnelly, Mr Peter 30-Jun MAMMO Non-Commercial Taunton and Somerset NHS Foundation Trust Thorne, Miss Amanda 30-Jun MAMMO Non-Commercial Yeovil District Hospital NHS Foundation Trust Ansari, Mr Bijan 30-Jun MANTA15689Non-Commercial Plymouth Hospitals NHS Trust Dubey, Dr Sid 03-Apr MANTA15689Non-Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 27-Apr

Breast Tumour Group South West Peninsula Open Studies 3 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrust Investigator Name End DateTargetRecruitment 2015/2016 Recruitment RTT NCRN Enzalutamide in Combination with Exemestane in Advanced Breast Cancer 15943Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 28-Mar NCRN384 - KATHERINE13395Commercial Northern Devon Healthcare NHS Trust Scatchard, Dr Kate 31-Mar NCRN384 - KATHERINE13395Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar NCRN522 PEGGY: PACLITAXEL + GDC-0941 vs PACLITAXEL + PLACEBO IN METASTATIC BREAST CANCER 13693Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 31-Mar OPPORTUNE11583 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Apr PAKT Study16095 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 25-Apr PAKT Study16095 Non- Commercial Yeovil District Hospital NHS Foundation Trust Barthakur, Urmila 28-Feb PALLET17716 Non- Commercial Plymouth Hospitals NHS Trust Panwar, Dr Udaiveer 03-Sep PALLET17716 Non- Commercial Royal Cornwall Hospitals NHS Trust Wheatley, Dr Duncan 01-Sep Persephone4078 Non- Commercial Northern Devon Healthcare NHS Trust Hwang, Dr David 31-Jul Persephone4078 Non- Commercial South Devon Healthcare NHS Foundation Trust Goodman, Dr Andrew 30-Jun Persephone4078 Non- Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini 30-Jun Persephone4078 Non- Commercial Yeovil District Hospital NHS Foundation Trust Sparrow, Dr Geoff 30-Jun

Breast Tumour Group South West Peninsula Open Studies 4 Data from CRN SWP Activity Data from EDGE July 2015 AcronymUKCRN IDStudy TypeTrustInvestigator NameEnd DateTargetRecruitment 2015/2016 Recruitment RTT POSNOC16069Non-CommercialRoyal Cornwall Hospitals NHS TrustAhmad, Mr Sheikh31-Mar POSNOC16069Non-Commercial Yeovil District Hospital NHS Foundation Trust Osborne, Ms Caroline31-Mar RAPPER1471Non-CommercialPlymouth Hospitals NHS TrustNatale, Mr Salvatore31-Aug RAPPER1471Non-Commercial Royal Devon and Exeter NHS Foundation Trust Srinivasan, Dr Rajaguru31-Aug RAPPER1471Non-Commercial South Devon Healthcare NHS Foundation Trust Lydon, Dr Anna31-Aug RAPPER1471Non-Commercial Taunton and Somerset NHS Foundation Trust Varughese, Dr Mohini31-Aug SEARCH1390Non-Commercial Northern Devon Healthcare NHS Trust Scatchard, Dr Kate30-Sep SEARCH1390Non-Commercial Royal Devon and Exeter NHS Foundation Trust Investigator, No Local30-Sep SEARCH1390Non-Commercial Taunton and Somerset NHS Foundation Trust Cattell, Dr Emma30-Sep SEARCH1390Non-Commercial Yeovil District Hospital NHS Foundation Trust Barlow, Dr Clare31-Dec UNIRAD17765Non-CommercialRoyal Cornwall Hospitals NHS TrustWheatley, Dr Duncan01-Dec

Division 1 Duncan Wheatley, Clinical Specialty Lead Wendy Cook, Research Delivery Manager Ann Courtman, Administrator